1. Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinomaBlaž Krhin, Katja Goričar, Barbara Gazić, Vita Dolžan, Nikola Bešić, 2016, original scientific article Abstract: Hurthle cells of the thyroid gland are very rich in mitochondria and oxidative enzymes. As a high level oxidative metabolism may lead to higher level of oxidative stress and can be associated with an increased risk for cancer, we investigated whether common functional polymorphisms in antioxidant genes (SOD2, CAT, GPX, GSTP1, GSTM1 and GSTT1) are associated with the development or clinical course of Hurthle cell thyroid carcinoma (HCTC). Methods. A retrospective study was performed in 139 patients treated by thyroid surgery for a Hurthle cell neoplasm. HCTC, Hurthle cell thyroid adenoma (HCTA) or Hurthle cell thyroid nodule (HCTN) were diagnosed by pathomorphology. DNA was extracted from cores of histologically confirmed normal tissue obtained from formalin-fixed paraffinembedded specimens and genotyped for investigated polymorphisms. Logistic regression was used to compare genotype distributions between patient groups. Results. HCTC, HCTA and HCTN were diagnosed in 53, 47 and 21 patients, respectively. Metastatic disease and recurrence of HCTC were diagnosed in 20 and 16 HCTC patients, respectively. Genotypes and allele frequencies of investigated polymorphisms did not deviate from Hardy-Weinberg equilibrium in patients with HCTC, HCTA and HCTN. Under the dominant genetic model we observed no differences in the genotype frequency distribution of the investigated polymorphisms when the HCTA and HCTN group was compared to the HCTC group for diagnosis of HCTC or for the presence of metastatic disease. However, GPX1 polymorphism was associated with the occurrence of recurrent disease (p = 0.040). Conclusions. GPX1 polymorphism may influence the risk for recurrent disease in HCTC. Keywords: Hurthle cell thyroid carcinoma, Hurthle cell neoplasm, thyroid, oxidative stress Published in DiRROS: 30.04.2024; Views: 62; Downloads: 6 Full text (522,00 KB) |
2. Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal : a single institution experienceNikola Bešić, Marta Dremelj, Andreja A. Schwarzbartl-Pevec, Barbara Gazić, 2015, original scientific article Abstract: There is a paradigm that chemotherapy is ineffective in thyroid carcinoma. The aim of our study was to find out whether neoadjuvant chemotherapy before thyroid surgery had an effect on the size of primary tumour in patients with poorly differentiated thyroid carcinoma (PDTC) based on Turin proposal. Patients and methods. Altogether, 13 patients (8 women, 5 men; median age 61 years) with PDTC based on Turin proposal were treated with neoadjuvant chemotherapy between 1986 and 2005. Tumour diameter was from 4.5 to 18 cm (median 9 cm). Regional and distant metastases were detected in 6 and 9 patients, respectively. Eight patients had pT4 tumour. Results. Altogether, 29 (range 1%5) cycles of chemotherapy were given. Tumour diameter decreased in all the patients and by more than 30% in 5 patients (= 38%). Two of these five patients had also preoperative external beam irradiation (EBRT). Total thyroidectomy, lobectomy and neck dissection were performed in 10, 3 and 5 cases, respectively. R0 and R1 resection was done in 5 and 8 cases, respectively. Eight patients had postoperative EBRT of the neck and upper mediastinum. The 5-year and 10-year cause-specific survival rates of patients were 66% and 20%, respectively. Conclusions. After neoadjuvant chemotherapy a partial tumour regression was observed in 38% of patients with PDTC based on Turin proposal. Keywords: poorly differentiated thyroid carcinoma, neoadjuvant, chemotherapy, survival Published in DiRROS: 22.04.2024; Views: 47; Downloads: 18 Full text (459,46 KB) |
3. |
4. |
5. Izraženost ER in PR pri invazivnem karcinomu dojke : rezultati določanja na 15 029 zaporednih vzorcih z Onkološkega Inštituta v obdobju 2006 do 2021Primož Drev, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Barbara Gazić, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija Published in DiRROS: 14.02.2023; Views: 426; Downloads: 129 Full text (79,90 KB) |
6. Izraženost hormonskih receptorjev pri invazivnem karcinomu dojke : rezultati določanja na 15029 zaporednih vzorcih z Onkološkega Inštituta v obdobju od 2006 do 2021Barbara Gazić, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Primož Drev, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija Published in DiRROS: 14.02.2023; Views: 411; Downloads: 93 Full text (87,23 KB) |
7. HER2 pri invazivnem karcinomu dojke – rezultati določanja na 15 184 zaporednih vzorcih z Onkološkega Inštituta v obdobju 2006 do 2021Primož Drev, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Barbara Gazić, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija Published in DiRROS: 14.02.2023; Views: 372; Downloads: 98 Full text (107,23 KB) |
8. Prediktivna vloga tumorske limfocitne infiltracije za dosego popolnega patološkega odgovora po predoperativnem sistemskem zdravljenju pri zgodnjem raku dojkeKlara Geršak, Barbara Gazić, Andreja Klevišar Ivančič, Primož Drev, Nina Ružić Gorenjec, Cvetka Grašič-Kuhar, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, kemoterapija Published in DiRROS: 03.02.2023; Views: 416; Downloads: 100 Full text (38,68 KB) |
9. |
10. Vpliv opustitve dopolnilne kemoterapije na preživetje bolnic z zgodnjim ER+/HER2+ rakom dojkValentina Jerič Horvat, Damjan Manevski, Barbara Gazić, Primož Drev, Domen Ribnikar, Erika Matos, Boštjan Šeruga, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, kemoterapija Published in DiRROS: 27.01.2023; Views: 387; Downloads: 109 Full text (47,33 KB) |